Protective Effect of Marine Peptides/Toxins in CVD Using Zebrafish Model
Diseases occurring in heart or blood vessels are known as cardiovascular diseases (CVDs). Myocardial infarction and angina are commonly known as heart attack, and they are also known as coronary artery diseases (CADs). Other CVDs include stroke, heart failure, hypertensive, rheumatic heart diseases, cardiomyopathy, heart arrhythmia, congenital heart disease, alular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease and venous thrombosis. About 90% of CVDs are preventable. CVD can be prevented by good eating habit, regular exercise, avoiding tobacco and smoke and limited alcohol intake. The zebrafish (Danio rerio) is an excellent model for studies of CVD and CAD. Bioactive macromolecules derived from marine materials and biopeptides are enhance our health promotion and reduces diseases risk. This chapter reveals that marine peptides could be used as an antihypertensive agent, and that the zebrafish provides an alternative in vivo model to efficiently evaluate the antihypertensive properties of marine peptides.
KeywordsAntihypertensive agent Coronary artery diseases Marine peptides Mediterranean diet Physical activity Statins
The support provided by the Department of Biotechnology, Ministry of Science and Technology, Government of India (To Dr. Senthilkumar Rajagopal – No: BT/RLF/Reentry/42/2012) to complete this chapter in a successful manner is gratefully acknowledged.
- Arun C, Duvoor C, Reddy Dendi V, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat N, Montales M, Kuriakose K, Sasapu A, Beebe A, Patil N, Musham C, Lohani G, Mirza W (2017) Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol 8:6Google Scholar
- Chablais F, Jazwinska A (2012) The regenerative capacity of the zebrafish heart is dependent on TGFβ signaling. Dev Stem Cell 139:1921–1930Google Scholar
- Dietrich M, Jacques P, Pencina M, Lanier K, Keyes M, Kaur G, Wolf P, D’Agostino R, Vasan R (2009) Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role? Atherosclerosis 205:549–553CrossRefGoogle Scholar
- Kotchen T (2010) The search for strategies to control hypertension. Hypertension 122:1141–1143Google Scholar
- Pinto I, Martins D (2017) Prevalence and risk factors of arterial hypertension: a literature review. J Cardiovasc Med Ther 1:1–7Google Scholar
- Ramkumar S, Raghunath A, Raghunath S (2016) Statin therapy: review of safety and potential side effects. Acta Cardiol Singapore 33:631–639Google Scholar
- Richard E, Couri D (2011) Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011:495349Google Scholar
- Wang H, Yuanyuan C, Yang X, Zhiyi M, Fan Y, Xining L, Ningling S (2017) Aspirin usage in patients with essential hypertension. BMJ Heart 97:A203Google Scholar